Content analysis and risk assessment of aristolochic acids in Chinese medicinal materials (decoction pieces)

doi:10.19803/j.1672-8629.20220175

Abstract

Abstract: Objective To analyze the content of aristolochic acid analogues in Chinese medicinal materials (decoction pieces) and carry out preliminary risk assessment. Methods Based on related literature published over the past 10 years, the contents of aristolochic acid analogues in 478 samples of 12 types of Chinese medicinal materials (decoction pieces) were analyzed in terms of distribution, correlations and sample difference. Starting from hazard identification to hazard characterization, exposure assessment and risk characterization, the calculation formulas and specific parameters were defined, and the target hazard quotient (THQ) was used to evaluate the safety risk of aristolochic acid I in Asari Radix et Rhizoma. Results Twenty-five types of aristolochic acid analogues were detected in 478 samples of 12 types of Chinese medicinal materials (decoction pieces). In general, the content of aristolochic acid I was the highest and that of aristolochic acid F1 was the lowest. There were correlations between contents of some components. The contents of aristolochic acids in the fruits of medicinal plants were much higher than those in other parts, and the contents of aristolochic acids decreased significantly after processing. Based on the statistics of legal medicinal parts, there were significant differences in the contents of aristolochic acid I and aristolochic acid П between different varieties, with contents in Aristolochiae Cinnabaria Radix being the highest and contents in Houttuyniae Herba being the lowest. The results of risk assessment showed that the target hazard quotient (THQ) of aristolochic acid I in one of the 11 samples of Asari Radix et Rhizoma was above 1, indicating that there was a safety risk. Conclusion The current contents and risk assessment method of aristolochic acids in Chinese medicinal materials (decoction pieces) obtained in this study can provide reference for quality control and safe use of Chinese medicinal materials (decoction pieces) containing aristolochic acids.

Key words: Chinese medicinal materials, decoction pieces, aristolochic acid I, aristolochic acid П, aristolochic acid F1, Asari Radix et Rhizoma, risk assessment

CLC Number:

R994.1

NIE Lixing, WANG Xinping, LI Jing, DAI Zhong, KANG Shuai, MA Shuangcheng. Content analysis and risk assessment of aristolochic acids in Chinese medicinal materials (decoction pieces)[J]. Chinese Journal of Pharmacovigilance, 2023, 20(5): 553-559.

References

[1] SONG HB, REN JT, YANG L, et al.Research progress on toxicity and risk factors analysis of aristolochic acid[J]. China Journal of Chinese Materia Medica(中国中药杂志), 2014, 39(12): 2246-2250.
[2] WU SH.Acute renal failure caused by Aristolochia manshuriensis: a report of two cases[J]. Jiangsu Journal of Traditional Chinese Medicine(江苏中医药), 1964 (10): 12-13.
[3] VANHERWEGHEM JL, DEPIERREUX M, TIELEMANS C, et al.Rapid progressive interstitial renal fibrosis in young women[J]. Lancet, 1993, 341(8842): 387-391.
[4] Medicine Control Agency of United Kingdom (UKMCA). UK MCA to ban certain herbals[J]. Scrip, 2001, 2611: 4.
[5] RAO XR, LI S, LI XY, et al.Analysis of two FDA notices on renal damage caused by Aristolochia Chinese herbal medicine[J]. Chinese Journal of Information on Traditional Chinese Medicine(中国中医药信息杂志), 2001, 8(2): 82-86.
[6] Chinese Pharmacopoeia Commission.Pharmacopoeia of the People’s Republic of China. VolumeⅠ(中华人民共和国药典一部)[M]. Beijing: China Medical Science Press, 2015: 51-52, 55, 230-231.
[7] WANG GB, CAO J, MA XH, et al.Requirements of FDA for preclinical toxicological studies on preparation of phytomedicine in U.S.[J]. Chinese Traditional and Herbal Drugs(中草药), 2013, 44(1): 116-119.
[8] Chinese Pharmacopoeia Commission.Pharmacopoeia of the People’s Republic of China. VolumeⅠ(中华人民共和国药典一部)[M]. Beijing: China Medical Science Press, 2020: 240-242.
[9] WANG DP, MAO XC.Research progress on traditional Chinese medicine containing aristolochic acid[J]. Journal of North Pharmacy(北方药学), 2014, 11(11): 97-98.
[10] LIANG AH, GAO Y, ZHANG BL.Safety problems and countermeasures of traditional Chinese medicine containing aristolochic acid[J]. China Food Drug Administration(中国食品药品监管), 2017, (11): 17-20.
[11] GAO Y, XIAO XH, ZHU XX, et al.Study and opinion on toxicity of aristolochic acid[J]. China Journal of Chinese Materia Medica(中国中药杂志), 2017, 42( 21): 4049-4053.
[12] LIU J, DAI Z, CHENG XL, et al.Research progress on detection and analysis of aristolochic acids[J]. Drug Evaluation Research(药物评价研究), 2019, 42(8): 1644-1650.
[13] LIU J, GUO RX, DAI Z, et al.Research progress of aristolochic acids[J]. Word Science and Technology/Modernization of Traditional Chinese Medicine and Materia Medica(世界科学技术中医药现代化), 2019, 21(7): 1280-1286.
[14] FU KY, XU ZC, SONG JY.Traditional Chinese medicine containing aristolochic acids and their detection[J]. Science Sinica Vitae(中国科学生命科学), 2019, 49(3): 238-249.
[15] SONG YG, MIAO YY, MIAO MS.Analysis on toxicity of traditional Chinese medicine containing aristolochic acid[J]. China Journal of Traditional Chinese Medicine and Pharmacy(中华中医药杂志), 2018, 33(5): 1950-1954.
[16] DING H, SHEN JZ, FEI WJ, et al.Determination of aristolochic acid A, B, C and D in Aristolochia herbs by UPLC-MS/MS[J]. Chinese Journal of Ethnomedicine and Ethnopharmacy(中国民族民间医药), 2018, 27(18): 38-43.
[17] KONG DQ, GAO HY, LI X, et al.Rapid determination of eight aristolochic acid analogues in five Aristolochiaceae plants by ultra-high performance liquid chromatography quadrupole/time-of-flight mass spectrometry[J]. Journal of Chinese Pharmaceutical Sciences(中国药学), 2015, 24(6): 364-375.
[18] GAO CK, GAO YJ, ZHANG N, et al.Simultaneous determination of five constituents in pericarps and seeds of Aristolochia herbs by UPLC-MS[J]. Chinese Traditional Patent Medicine(中成药), 2021, 43(10): 2750-2754.
[19] LIU XX, WANG L, XIAO HB.Content of total aristolochic acid in Aristolochia debilis from different localities[J]. LISHIZHEN Medicine and Materia Medica Research(时珍国医国药), 2017, 28(1): 74-76.
[20] REN HZ.Determination of the content of aristolochic acid A in processed Aristolochia Cinnabarina by HPLC[J]. Asia-Pacific Traditional Medicine(亚太传统医药), 2015, 11(11): 23-25.
[21] GUO N, ZHAO Y, SUN Y, et al.Qualitative and quantitative analysis of aristolochic acids in Aristolochia cinnabarina dried root tubers by UPLC-QTOF-MS/MS[J]. Chinese Journal of Experimental Traditional Medical Formulae(中国实验方剂学杂志), 2021, 27(11): 162-170.
[22] MIAO QH, ZHANG ZQ, MIN XD, et al.Qualitative and quantitative determination of aristolochic acids in Houttuynia cordata by high performance liquid chromatography-tandem mass spectrometry[J]. Journal of Food Safety and Quality(食品安全质量检测学报), 2021, 12(13): 5299-5305.
[23] MI SL.Qualitative and quantitative study on toxic substances of aristolochic acid components in nine Chinese medicinal materials[D]. Nanjing: Nanjing University of Chinese Medicine(南京中医药大学), 2021.
[24] LI GH, CHEN S, WU L, et al.Determination of aristolochic acid I in traditional Chinese medicine by UPLC-QQQ-MS[J]. Chinese Journal of Experimental Traditional Medical Formulae(中国实验方剂学杂志), 2017, 23(13): 61-65.
[25] ZHANG JL, GONG QF, YAO DQ.Determination of aristolochic acid A in different parts of Aristolochia from different habitats by HPLC[C]. 2012 Proceedings of the Fifth National Symposium on Clinical Traditional Chinese Medicine, 2012.
[26] ZHANG YM, LI YS, SUN WX, et al.Content changes of Aristolochic acid-A from caulis Aristolochiae manshuriensis and its processed Products[J]. Chinese Medicine Modern Distance Education of China(中国中医药现代远程教育), 2012, 10(6): 154-156.
[27] LI TF, LI LK, ZHANG ML, et al.Determination of aristolochic acid in Aristolochia Manshuriensis with different processing methods by RP-HPLC[J]. China medical Herald(中国医药导报), 2015, 12(21): 14-17.
[28] ZHANG P.Determination of aristolochic acid A in different organs of Valeriana Jatamansi by UV spectrophotometry[J]. Value Engineering(价值工程), 2012, 31(1): 293-294.
[29] YU Y, WANG XR, WEI XZ, et al.Determination of total aristolochic acids in three kinds of Asarum[J]. Journal of Liaoning University of TCM(辽宁中医药大学学报), 2013, 5(10): 44-45.
[30] ZHU ZX.Determination of aristolochic acid A in different parts of Asarum by HPLC[J]. LISHIZHEN Medicine and Materia Medica Research(时珍国医国药), 2015, 26(10): 2394-2395.
[31] ZENG C, LIU XM, MENG WX, et al.Determination of aristolochic acid in Herba Asarum from different habitats by HPLC[J]. Internal Medicine(内科), 2013, 8(1): 56-57.
[32] ZHANG CY, YU J, LIU GX, et al.Distribution and content analysis of three kinds of aristolochic acid and two kinds of aristolochia lactam in different parts of three kinds of Asarum[J]. Word Science and Technology/Modernization of Traditional Chinese Medicine and Materia Medica(世界科学技术中医药现代化), 2019, 21(7): 1295-1305.
[33] ZUO TT, WANG Y, ZHANG L, et al.Guideline of risk assessment of exogenous harmful residues in traditional Chinese medicines[J]. Chinese Journal of Pharmaceutical Analysis, 2019, 39(10): 1902-1907.
[34] MENG SU.Acute toxicity of aristolochic acid in rodents[J]. Archives of Toxicology, 1987, 59(5): 328-331.
[35] WU F, WANG T.Risk assessment of upper tract urothelial carcinoma related to aristolochic acid[J]. Cancer Epidemiology Biomarkers and Prevention, 2013, 22(5): 812-820.
[36] JONG TT, LEE MR, HSIAO SS, et al.Analysis of aristolochic acid in nine sources of Xixin, a traditional Chinese medicine, by liquid chromatography/atmospheric pressure chemical ionization/tandem mass spectrometry[J]. Journal of Pharmaceutical & Biomedical Analysis, 2003, 33(4): 831-837.
[37] BARNES DG, DASTON GP, EVANS JS, et al.Benchmark dose workshop: criteria for use of a benchmark dose to estimate a reference dose[J]. Regulatory Toxicology & Pharmacology Rtp, 1995, 21(2): 296-306.
[38] LAI MN, WANG SM, CHEN PC, et al.Population-based case-control study of Chinese herbal products containing aristolochic acid and urinary tract cancer risk[J]. JNCI: Journal of the National Cancer Institute, 2010, 102(3): 179-186.
[39] ZHANG HM, ZHAO XH, SUN ZH, et al.Recognition of the toxicity of aristolochic acid[J]. Journal of Clinical Pharmacy and Therapeutics, 2019, 44(2): 157-162.
[40] MAO WF, WANG YBN, ZUO TT, et al.Risk assessment of lead exposure of Chinese medicinal herbs in Chinese population[J]. Drug Standards of China, 2018, 19(4): 275-281.
[41] WANG YBN, JIN HY, ZHANG L.The situation investigation of traditional Chinese medicine adult consumers in 11 provinces of China[J]. Journal of Yunnan University of Traditional Chinese Medicine, 2017, 40(2): 71-75.
[42] WANG YBN, LIU AD, LI JW, et al.The survey of traditional Chinese medicine consumption among adult residents in 11 provinces and cities[J]. Chinese Pharmaceutical Affairs, 2017, 31(6): 666-672.
[43] LI WH, YANG L, SU T, et al.Influence of taking aristolochic acid-containing Chinese drugs on occurrence of urinary transitional cell cancer in uremic patients undergoing dialysis[J]. China Journal of Traditional Chinese Medicine and Pharmacy(中华医学杂志), 2005, 85(35): 2487-2491.
[44] U.S.Environmental Protection Agency. IRIS Summaries Chromium(VI)(CASRN 1854002909) [R]. Washington DC: U.S. Environmental Protection Agency, 1998.
[45] LI GH, CHEN S, ZHANG J, et al.Explore a method for formulation of limit standard of toxic components in traditional Chinese medicine: aristolochic acid as a case study[J]. China Journal of Chinese Materia Medica(中国中药杂志), 2017, 42(4): 800-804.